Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display.

Show less

Author information

Affiliations

  • 1. Research Division, Chugai Pharmaceutical Co. Ltd., 216, Totsuka-cho, Totsuka-ku, Yokohama, Kanagawa 244-8602, Japan.
      Authors
    • Kage M 1
    • Hayashi R 1
    • Matsuo A 1
    • Tamiya M 1
    • Kuramoto S 1
    • Ohara K 1
    • Irie M 1
    • Chiyoda A 1
    • Takano K 1
    • Ito T 1
    • Kotake T 1
    • Takeyama R 1
    • Ishikawa S 1
    • Nomura K 1
    • Furuichi N 1
    • Morita Y 1
    • Hashimoto S 1
    • Kawada H 1
    • Nishimura Y 1
    • Nii K 1
    • Sase H 1
    • Ohta A 1
    • Kojima T 1
    • Iikura H 1
    • Tanada M 1
    • Shiraishi T 1
    (26 authors)

ORCIDs linked to this article

Bioorganic & Medicinal Chemistry, 06 Jul 2024, 110:117830
https://doi.org/10.1016/j.bmc.2024.117830 PMID: 38981216 

Abstract 

Cyclic peptides are attracting attention as therapeutic agents due to their potential for oral absorption and easy access to tough intracellular targets. LUNA18, a clinical KRAS inhibitor, was transformed-without scaffold hopping-from the initial hit by using an mRNA display library that met our criteria for drug-likeness. In drug discovery using mRNA display libraries, hit compounds always possess a site linked to an mRNA tag. Here, we describe our examination of the Structure-Activity Relationship (SAR) using X-ray structures for chemical optimization near the site linked to the mRNA tag, equivalent to the C-terminus. Structural modifications near the C-terminus demonstrated a relatively wide range of tolerance for side chains. Furthermore, we show that a single atom modification is enough to change the pharmacokinetic (PK) profile. Since there are four positions where side chain modification is permissible in terms of activity, it is possible to flexibly adjust the pharmacokinetic profile by structurally optimizing the side chain. The side chain transformation findings demonstrated here may be generally applicable to hits obtained from mRNA display libraries.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.bmc.2024.117830

Citations & impact 

This article has not been cited yet.

Impact metrics

Alternative metrics

Altmetric item for https://www.altmetric.com/details/165210721
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/165210721

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.